Literature DB >> 10620701

Primary response of naive CD4(+) T cells to amino acid-substituted analogs of an antigenic peptide can show distinct activation patterns: Th1- and Th2-type cytokine secretion, and helper activity for antibody production without apparent cytokine secretion.

W Ise1, M Totsuka, R Takato, S Hachimura, T Sato, A Ametani, Y Kumagai, S Habu, S Kaminogawa.   

Abstract

Naive CD4(+) T cells differentiate into two types of helper T cells showing an interferon-gamma-predominant (Th1) or an interleukin-4-predominant (Th2) cytokine secretion profile after repeated antigenic stimulation. Their differentiation can be influenced by slight differences in the interaction between the T cell receptor (TCR) and its ligand at the time of primary activation. However, the primary response of freshly isolated naive CD4(+) T cells to altered TCR ligands is still unclear. Here, we investigated the primary response of splenic naive CD4(+) T cells derived from transgenic mice expressing TCR specific for residues 323-339 of ovalbumin (OVA323-339) bound to I-A(d) molecules. Naive CD4(+) T cells secreted either Th1- or Th2-type cytokines immediately after stimulation with OVA323-339 or its single amino acid-substituted analogs. Helper activity for antibody secretion by co-cultured resting B cells was also found in the primary response, accompanied by either low-level Th2-type cytokine secretion or no apparent cytokine secretion. Our results clearly indicate that dichotomy of the Th1/Th2 cytokine secretion profile can be elicited upon primary activation of naive CD4(+) T cells. We also demonstrate that the helper activity of naive CD4(+) T cells for antibody production does not correspond to the amounts of the relevant cytokines secreted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620701     DOI: 10.1016/s0014-5793(99)01716-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Interleukin 12 and CD86 Regulate Th1 and Th2 Development Induced by a Range of Antigen Doses Presented by Peyer's Patch and Spleen Cells.

Authors:  Tadashi Yoshida; Satoshi Hachimura; Mina Ishimori; Wataru Ise; Mamoru Totsuka; Akio Ametani; Shuichi Kaminogawa
Journal:  Cytotechnology       Date:  2003-11       Impact factor: 2.058

2.  Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Authors:  Soili A Saarelainen; Tuure T Kinnunen; Cécile Buhot; Ale T O Närvänen; Anu K Kauppinen; Marja A Rytkönen-Nissinen; Bernard Maillere; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

3.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

4.  Orally tolerant CD4 T cells respond poorly to antigenic stimulation but strongly to direct stimulation of intracellular signaling pathways.

Authors:  K Asai; S Hachimura; T Toraya; S Kaminogawa
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

5.  Enhancement of Oral Tolerance Induction in DO11.10 Mice by Lactobacillus gasseri OLL2809 via Increase of Effector Regulatory T Cells.

Authors:  Ayako Aoki-Yoshida; Kiyoshi Yamada; Satoshi Hachimura; Toshihiro Sashihara; Shuji Ikegami; Makoto Shimizu; Mamoru Totsuka
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

6.  Comparison of antibody responses against Mycobacterium tuberculosis antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study.

Authors:  Jingge Zhao; Takashi Matsuba; Xiaoyan Zhang; Susan Leano; Chie Nakajima; Haorile Chagan-Yasutan; Elizabeth Freda Telan; Yasuhiko Suzuki; Toshio Hattori
Journal:  BMC Infect Dis       Date:  2017-05-15       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.